Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Yano M, Ikemoto F
New Drug Discovery Research Laboratories, Banyu Pharmaceutical Co., Ltd., Tsukuba, Japan.
Eur J Pharmacol. 1992 Oct 6;221(1):77-83. doi: 10.1016/0014-2999(92)90774-x.
To elucidate the pathophysiological role of endogenous endothelin (ET), we examined the effects of the newly synthesized ETA receptor-selective antagonist, BQ-123, on ischemic acute renal failure induced by bilateral clamping of renal artery and vein followed by reperfusion in rats. BQ-123, when given by i.v. infusion of 0.5 mg/kg per min for 2.5 h during the pre- and post-ischemic period, was found to prevent the decrease in creatinine clearance and increases in blood urea nitrogen, plasma creatinine and the fractional excretion of sodium. Morphological observation also showed an effect of BQ-123, i.e. prevention of proximal tubular (S3 segment) necrosis. At 2 h after the start of reperfusion, the ET-1 content in the kidney increased to its maximal level. At this time, the Ca2+ content in the mitochondrial fraction of the renal cortex increased, with a concomitant increase in blood urea nitrogen. However, these increases were limited by treatment with BQ-123. Thus, BQ-123 was effective to both prevent mitochondrial Ca2+ accumulation in the early phase of ischemic acute renal failure and protect proximal tubular cells from post-ischemic degeneration. We conclude that ET may be at least partially involved in the pathogenesis of tubular cell injury in this acute renal failure model.
为阐明内源性内皮素(ET)的病理生理作用,我们研究了新合成的ETA受体选择性拮抗剂BQ-123对大鼠肾动脉和肾静脉双侧夹闭后再灌注诱导的缺血性急性肾衰竭的影响。发现在缺血前期和缺血后期,以每分钟0.5mg/kg的速度静脉输注BQ-123 2.5小时,可防止肌酐清除率降低以及血尿素氮、血浆肌酐和钠分数排泄增加。形态学观察也显示了BQ-123的作用,即预防近端小管(S3段)坏死。再灌注开始后2小时,肾脏中的ET-1含量增加到最高水平。此时,肾皮质线粒体部分的Ca2+含量增加,同时血尿素氮也增加。然而,这些增加受到BQ-123治疗的限制。因此,BQ-123在缺血性急性肾衰竭早期有效防止线粒体Ca2+积累,并保护近端小管细胞免于缺血后变性。我们得出结论,在这个急性肾衰竭模型中,ET可能至少部分参与了肾小管细胞损伤的发病机制。